With an improved understanding of biology and mechanisms of action, the Wnt/B-Catenin community is surging through clinic in 2022 with positive clinical updates. The excitement of a potential first-in-class candidate to advent combination, immuno-oncology therapies in colorectal, head and neck and non-small cell lung cancer is offering hope for patients with high unmet medical needs.

After 2 decades of research, it is now the time for drug developers to act and get together at the 2nd Wnt/B-Catenin Pathway Targeted Drug Development Summit. As the one and only industry-led meeting, you will be equipped with unparalleled insights in:

- Wnt/B-Catenin's structural biology and medicinal chemistry - turning the undruggable druggable

- Comparison of different Wnt/B-Catenin modulation approaches, its interaction with TIL and tumor microenvironment for targeted, combination therapies

- Translating basic science into clinical design - from scheduling to dosing, overcoming toxicity to widen the therapeutic window with safety in mind

- Validating a clinical biomarker for patient selection

In collaboration with Wnt/B-Catenin pioneers such as Iterion Therapeutics, Leap Therapeutics, FogPharma, this is your unique opportunity to join and meet 60+ drug developers to forge long-term collaboration and advance Wnt/B-Catenin as a valuable target and clinical asset, propelling to provide first-in-class treatments for patients!

Continue reading at nt-b-catenindrugdevelopment.com

Family Medicine / Family Practice

Facebook Share

Twitter Share

Linkedin Share

Email Share